Advent Venture Partners
VC Fund
London, United Kingdom
Advent Venture Partners is a VC fund in London focused on Biotechnology and Health Care. Advent Venture Partners is one of Europe's most successful growth and venture capital investors in market-leading tech and life sciences businesses. They have designed their strategy, teams and funds so they can focus on backing a select few companies. They pride their selves on establishing true partnerships with entrepreneurs in order tobuild valuable businesses together.
- Total investments:
- 91
- Last investment:
- Lead investor:
- 32%
- Fund size:
- $25M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Advent Venture Partners invests in
Stages Advent Venture Partners invests in
Countries Advent Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $6.6M–$26M
- Series B
- $7M–$50M
Investment Focus
Industry
- Biotechnology 22 (24%)
- Health Care 21 (23%)
- Software 11 (12%)
- Medical 9 (10%)
- Therapeutics 6 (7%)
Stage
- Series B 24 (26%)
- Series A 18 (20%)
- Funding Round 17 (19%)
- Series C 16 (18%)
- Series D 9 (10%)
Country
- United Kingdom 23 (25%)
- United States 21 (23%)
- Switzerland 4 (4%)
- France 2 (2%)
- Israel 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Don Drakeman
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Les Gabb
Founder & Finance Partner
|
Founder & Finance Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Wiz
|
Wiz is a cloud security platform that enables organizations to enhance collaboration among security, development, and DevOps teams while facilitating a self-service model for managing cloud infrastructure and identifying potential risks. The platform provides comprehensive visibility across cloud environments, allowing users to detectvulnerabilities, misconfigurations, and compliance issues in real-time. By integrating seamlessly with existing workflows and tools, Wiz supports automated security assessments and prioritizes remediation efforts based on risk levels, helping teams to maintain security without hindering development speed. Additionally, Wiz offers insights into cloud usage patterns and security posture, empowering organizations to make informed decisions regarding their cloud strategy. | $130M / Series B / Mar 17, 2021 | |
Acutus Medical
|
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California. | $100M / Series D / Jun 20, 2019 | |
WorldStores
|
Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories.ACHICA, the luxury flash-sale business, and baby specialistKiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market. | $38.4M / Series D / Mar 03, 2015 | |
Farfetch
|
Farfetch operates an e-commerce website that unites various independent fashion boutiques. It offers bags, coats, dresses, jackets, jewellery, swimwear, trouser, shoes, knitwear, suits, shorts, and accessories. They operate a modular end-to-end technology platform purpose built to connect the luxury fashion ecosystem worldwide. Their vision wasto create a single operating system that could address the complex demands of consumers and luxury sellers alike. Their platform is built on an API-enabled proprietary technology stack, which provides the foundation for the three main components: applications, services and data. Farfetch serves women, men, and kids. Jose Neves founded the company in 2008, with its headquarters in London, United Kingdom. | $66M / Series D / May 01, 2014 | |
Versartis
|
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix.Headquartered in Redwood City, California,Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner.The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman. | $20M / Series D / Oct 08, 2013 | |
|
Acutus Medical
|
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California. | $28M / Series B / Aug 20, 2013 | |
|
Versartis
|
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix.Headquartered in Redwood City, California,Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner.The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman. | $12.5M / Series C / Jul 22, 2013 | |
|
WorldStores
|
Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories.ACHICA, the luxury flash-sale business, and baby specialistKiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market. | $15.2M / Series C / Jun 03, 2013 | |
|
Farfetch
|
Farfetch operates an e-commerce website that unites various independent fashion boutiques. It offers bags, coats, dresses, jackets, jewellery, swimwear, trouser, shoes, knitwear, suits, shorts, and accessories. They operate a modular end-to-end technology platform purpose built to connect the luxury fashion ecosystem worldwide. Their vision wasto create a single operating system that could address the complex demands of consumers and luxury sellers alike. Their platform is built on an API-enabled proprietary technology stack, which provides the foundation for the three main components: applications, services and data. Farfetch serves women, men, and kids. Jose Neves founded the company in 2008, with its headquarters in London, United Kingdom. | $20M / Series C / Mar 03, 2013 | |
|
Versartis
|
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix.Headquartered in Redwood City, California,Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner.The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman. | $25M / Series C / Jan 15, 2013 | |
| See all 91 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Advent Venture Partners invest in?
Advent Venture Partners invests primarily in Biotechnology, Health Care and Software startups, most often at Series B and Series A stage. Most of the 91 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Advent Venture Partners's check size?
Advent Venture Partners typically joins rounds of $6.6M–$26M at Series A and $7M–$50M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Advent Venture Partners participates in.
How do I contact Advent Venture Partners?
Public channels for Advent Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Advent Venture Partners?
The team at Advent Venture Partners includes Don Drakeman (Venture Partner) and Les Gabb (Founder & Finance Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
